Ovid Therapeutics (OVID) has disclosed a new risk, in the Taxation & Government Incentives category.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ovid Therapeutics faces significant business risks due to potential disruptions at the FDA and other government agencies. Factors such as layoffs, funding shortages, and global health concerns could impede the FDA’s ability to review clinical trials or approve new products. These disruptions may lead to delays in product development and approval processes, adversely affecting Ovid’s business operations. The unpredictability of government funding and policy changes further exacerbates these risks, posing a challenge to the company’s strategic planning and execution.
Overall, Wall Street has a Strong Buy consensus rating on OVID stock based on 6 Buys and 1 Hold.
To learn more about Ovid Therapeutics’ risk factors, click here.